Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05374915 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
A Phase 2 study of Cutaneous Breast Cancer, sponsored by Kintara Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT05374915 is a Phase 2 study of Cutaneous Breast Cancer that is active but no longer recruiting, run by Kintara Therapeutics. The registered enrollment target is 15 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT05374915, a Phase 2 study of Cutaneous Breast Cancer, is active but no longer recruiting, sponsored by Kintara Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, single cohort study to confirm dose, assessments and timing of response, to support future studies. The primary objective of the trial is to evaluate cutaneous tumor response within total target treatment field to REM-001 therapy assessed using standardized digital photography
Conditions Studied
Interventions
- COMBINATION_PRODUCT REM-001 photodynamic therapy
Study Locations (2)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Montefiore Einstein Center for Cancer Care - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05374915
The ClinicalTrials.gov registry entry for NCT05374915 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kintara Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which REM-001 photodynamic therapy is the first listed.
NCT05374915 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05374915 about?
NCT05374915 is a clinical study titled "Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)". This is an open-label, single cohort study to confirm dose, assessments and timing of response, to support future studies. The primary objective of the trial is to evaluate cutaneous tumor response within total target treatment field to REM-001 therapy assessed using standardized digital photography
What is the current status of trial NCT05374915?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2024-02-12. Estimated completion is 2025-12-31.
What conditions does trial NCT05374915 study?
This clinical trial studies the following conditions: Cutaneous Breast Cancer.
What interventions are being tested in trial NCT05374915?
The interventions under investigation include: REM-001 photodynamic therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05374915?
This trial is sponsored by Kintara Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05374915 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.